Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2002

Filing Date
Filed March 20, 2003
Period End
December 31, 2002
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’19Oct ’19
  3. Material agreement8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 20, 2003. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' 2002 10-K shows a company that grew revenue 7% to $412.7 milliona and net income 21% to $45.4 million (diluted EPS $1.30, up from $1.09).

Growth came mainly from the Companion Animal Group (CAG), which generated about 79% of sales and grew 6% to $326.9 millionb, while the Food and Environmental Group (FEG) grew 10% to $85.8 million. Gross margin held flat at 47%, and operating income rose 16% to $65.8 million, helped by the adoption of SFAS 142 (which ended goodwill amortization) and a $0.7 million reversal of an Ortho slide contract loss reserve, partly offset by $3.4 million in CEO succession charges and higher foreign exchange hedge losses. The balance sheet strengthened, with cash and investments of $162.8 million, working capital of $213.4 million, and total debt reduced to under $1 million.

Operating cash flow was $103.3 millionc, and the company repurchased 1.0 million shares for $29.8 million. Management expects no dividends, and capital spending of about $19.8 million is planned for 2003. Investors should watch several risks: a $232.4 million minimum purchase obligation for VetTest slides from Ortho, a nitazoxanide pharmaceutical awaiting FDA approval with $8.4 million of inventory at risk, a LaserCyte hematology launch that will raise warranty costs, heavy reliance on distributor inventory levels, and a 29% international revenue mix that adds currency exposure (a 10% dollar strengthening would cut operating income by about $5.3 million after hedges).

Key Highlights

  1. Revenue rose 7% to $412.7M (2001: $386.1M); CAG grew 6% to $326.9M and FEG grew 10% to $85.8M.
  2. Net income rose 21% to $45.4M; diluted EPS $1.30 vs. $1.09, aided by a lower share count from buybacks.
  3. Gross margin was flat at 47%, while operating income rose 16% to $65.8M and operating margin reached 16%.
  4. Strong balance sheet: $162.8M in cash and investments, $213.4M working capital, and total debt of only $1.0M.
  5. Operating cash flow of $103.3M; 1.0M shares repurchased for $29.8M; no dividends paid or planned.
  6. Key risks: $232.4M minimum VetTest slide purchase obligation to Ortho, $8.4M of nitazoxanide inventory dependent on FDA approval, and LaserCyte launch costs.
  7. Accounting changes: SFAS 142 ended goodwill amortization (about $4.5M benefit), and a $3.4M CEO succession charge was recorded in 2002.

Frequently Asked Questions

  1. What drove IDEXX's revenue and profit growth in 2002?

    Revenue growth came mainly from laboratory services (+$7.3M), instrument consumables (+$6.2M, including VetTest slides), rapid assays (+$3.1M, or about 12% after adjusting for distributor inventory changes), and FEG livestock and water testing. Profit growth was supported by higher volume, productivity gains, and the end of goodwill amortization under SFAS 142, which offset higher sales and marketing spend and litigation costs.

  2. How exposed is IDEXX to its pharmaceutical pipeline and inventory write-downs?

    The company carried $8.4M of nitazoxanide inventory (active ingredient expiring in 2005) that depends on FDA approval, expected around late 2003. A delay or lower sales could require write-offs; for example, roughly $0.5M of additional expiry is possible under one scenario. If the FDA rejects the product, IDEXX may be able to return the active ingredient to its supplier at cost, but that supplier's ability to pay is not assured. Pharmaceutical revenue remained immaterial in 2002.

  3. What contractual commitments could affect future cash flows?

    Total contractual obligations are $287.4M, including $258.6M of unconditional purchase obligations. Of that, $232.4M is the minimum VetTest slide purchase commitment with Ortho through 2010 (extendable to 2011). The company reduced this commitment by 30 million slides (about $17.7M) in 2002 in exchange for forgoing about $2.0M of volume rebates. Losses could arise if slide demand per customer falls short of plan.

  4. What is the outlook for the LaserCyte hematology system and its impact on margins?

    LaserCyte launched in October 2002 with $1.9M of 2002 revenue and $3.3M of backlog at year-end. Management expects LaserCyte to lift instrument sales and, because IDEXX makes the consumables in-house, to carry higher consumable margins than the QBC VetAutoread product it partly replaces. However, warranty expense is expected to rise significantly in 2003, and consumable sales may not grow much near term because LaserCyte placements largely replace existing QBC units.